Entering text into the input field will update the search result below

NY clears Rosetta's thyroid cancer test; shares up 18%

Feb. 18, 2016 12:09 PM ETRosetta Genomics Ltd. (ROSG-OLD) StockBy: Douglas W. House, SA News Editor1 Comment
  • Thinly traded nano cap Rosetta Genomics (NASDAQ:ROSG-OLD +18.1%) is up on triple normal volume in response to its announcement that the State of New York has granted conditional approval for RosettaGX Reveal, its microRNA classifier for the diagnosis of indeterminate thyroid fine needle aspirate smears collected by the NY State Department of Health. It is the only molecular thyroid test to be so designated.
  • New York is the only U.S. state that requires separate licensure for CLIA-certified tests performed there. Its OK means that RosettaGX Reveal in now available in all 50 states.

Recommended For You

Related Stocks

SymbolLast Price% Chg
ROSG-OLD--
Rosetta Genomics Ltd.